These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 3293772

  • 1. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B.
    Cancer Res; 1988 Aug 15; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract] [Full Text] [Related]

  • 2. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS, Gralla RJ, Kemeny NE.
    Cancer Treat Rep; 1980 Aug 15; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract] [Full Text] [Related]

  • 3. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW.
    Cancer Treat Rep; 1980 Aug 15; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract] [Full Text] [Related]

  • 4. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C.
    Recent Results Cancer Res; 1980 Aug 15; 74():65-71. PubMed ID: 7444150
    [Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET, Eagan RT, Fleming TR, Frytak S, Nichols WC, Ingle JN, Kvols LK.
    Cancer Treat Rep; 1981 Aug 15; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract] [Full Text] [Related]

  • 6. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J, Purvis J, Britell JC, Hahn RG, Moertel CG, Schutt AJ.
    Cancer Treat Rep; 1981 Aug 15; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract] [Full Text] [Related]

  • 7. Response of psoriasis to N-phosphonacetyl-L-aspartate.
    Earhart RH, DeConti RC, Rubin J, Ohnuma T.
    Lancet; 1981 Jun 06; 1(8232):1257-8. PubMed ID: 6112581
    [No Abstract] [Full Text] [Related]

  • 8. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Jun 06; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 9. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET, Ahmann DL, Ingle JN, Purvis JD, Green SJ.
    Cancer Treat Rep; 1981 Jun 06; 65(1-2):169. PubMed ID: 6894400
    [No Abstract] [Full Text] [Related]

  • 10. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM, Anderson LW, Erlichman C, Cysyk RL.
    Cancer Res; 1980 Aug 06; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [Abstract] [Full Text] [Related]

  • 11. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
    Doyle JA, Perry HO, Rubin J, Moertel CG.
    J Am Acad Dermatol; 1984 Jan 06; 10(1):21-4. PubMed ID: 6229552
    [Abstract] [Full Text] [Related]

  • 12. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR, Mulder JH, Rümke P, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Aug 06; 18(8):723-6. PubMed ID: 6217975
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ, Blum RH, Meshad MW, Kufe DW, Johnson RK, Canellos GP.
    Cancer Treat Rep; 1980 Aug 06; 64(10-11):1067-71. PubMed ID: 7459892
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB, Yagoda A, Kelsen DP, Gralla RJ, Watson RC.
    Cancer Treat Rep; 1982 Dec 06; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
    Hart RD, Ohnuma T, Holland JF.
    Cancer Treat Rep; 1980 Dec 06; 64(4-5):617-24. PubMed ID: 6448687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.